Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical outcomes

BACKGROUND: Compound epidermal growth factor receptor (EGFR) mutations are less responsive to tyrosine kinase inhibitors (TKIs) than single EGFR mutations in non-small cell lung cancer (NSCLC). However, the detailed clinical characteristics and prognosis of various compound EGFR mutations remain to...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Weixin, Song, Ailing, Xu, Yang, Wu, Qian, Liu, Cuicui, Yin, Jiani C., Ou, Qiuxiang, Wu, Xue, Shao, Yang, Zhao, Xinmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960474/
https://www.ncbi.nlm.nih.gov/pubmed/36829178
http://dx.doi.org/10.1186/s12916-023-02768-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960474/
https://www.ncbi.nlm.nih.gov/pubmed/36829178
http://dx.doi.org/10.1186/s12916-023-02768-z

Ejemplares similares